share_log

Mangoceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Jacob D. Cohen(34.7%),The Tiger Cub Trust(28.6%)

Mangoceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Jacob D. Cohen(34.7%),The Tiger Cub Trust(28.6%)

Mangoceuticals | SC 13D/A:超过5%持股股东披露文件(修正)-Jacob D. Cohen(34.7%),The Tiger Cub Trust(28.6%)
美股SEC公告 ·  06/05 17:18
Moomoo AI 已提取核心信息
On June 3, 2024, Mangoceuticals, Inc. experienced a significant event involving its stock ownership. Jacob D. Cohen, the company's CEO and Chairman, received an issuance of 800,000 fully-vested shares of common stock as a bonus for the year 2024. This decision was approved by the Board of Directors with the recommendation of the Compensation Committee. The Schedule 13D/A filing with the SEC, which is an amendment to the previous filings, reflects this change. As a result, Jacob D. Cohen now beneficially owns 10,575,000 shares, representing 34.7% of the company's common stock. Additionally, The Tiger Cub Trust, also a reporting person, holds 8,275,000 shares, which accounts for 28.6% of the common stock. These ownership percentages are based on 28,943,143 shares of common stock outstanding as of June 5, 2024. The filing confirms that no other person has the right to receive dividends or proceeds from the sale of the securities owned by the reporting persons.
On June 3, 2024, Mangoceuticals, Inc. experienced a significant event involving its stock ownership. Jacob D. Cohen, the company's CEO and Chairman, received an issuance of 800,000 fully-vested shares of common stock as a bonus for the year 2024. This decision was approved by the Board of Directors with the recommendation of the Compensation Committee. The Schedule 13D/A filing with the SEC, which is an amendment to the previous filings, reflects this change. As a result, Jacob D. Cohen now beneficially owns 10,575,000 shares, representing 34.7% of the company's common stock. Additionally, The Tiger Cub Trust, also a reporting person, holds 8,275,000 shares, which accounts for 28.6% of the common stock. These ownership percentages are based on 28,943,143 shares of common stock outstanding as of June 5, 2024. The filing confirms that no other person has the right to receive dividends or proceeds from the sale of the securities owned by the reporting persons.
2024年6月3日,Mangoceuticals公司发生了一件涉及其股权的重大事件。该公司的CEO和主席Jacob D. Cohen因为2024年的奖金获得了80万股普通股的发行。此决定经董事会批准并在薪酬委员会的推荐下进行。Schedule 13D/A提交给SEC,这是对之前提交的申报的修改,反映了这一变化。因此,Jacob D. Cohen现在持有1057.5万股,代表该公司普通股的34.7%。此外,另一家上报单位The Tiger Cub Trust持有827.5万股,占普通股的28.6%。这些所有权百分比是基于截至2024年6月5日的2894.3143万股普通股。申报确认,没有其他人有权利获得分红或出售申报人所持证券的收益。
2024年6月3日,Mangoceuticals公司发生了一件涉及其股权的重大事件。该公司的CEO和主席Jacob D. Cohen因为2024年的奖金获得了80万股普通股的发行。此决定经董事会批准并在薪酬委员会的推荐下进行。Schedule 13D/A提交给SEC,这是对之前提交的申报的修改,反映了这一变化。因此,Jacob D. Cohen现在持有1057.5万股,代表该公司普通股的34.7%。此外,另一家上报单位The Tiger Cub Trust持有827.5万股,占普通股的28.6%。这些所有权百分比是基于截至2024年6月5日的2894.3143万股普通股。申报确认,没有其他人有权利获得分红或出售申报人所持证券的收益。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息